Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 26-Jan-21 5:07 PM View:  | Nussbaum Ran Director | Prevail Therapeutics Inc. (PRVL) | 22-Jan-21 | Disposition (change in control) | 1,576,880 | -- | -- | (100%) 1.58M to 0 | |
| 26-Jan-21 5:19 PM View: | Abeliovich Asa President & CEO Director | Prevail Therapeutics Inc. (PRVL) | 22-Jan-21 | Disposition (change in control) | 2,385,760 | -- | -- | (100%) 2.39M to 0 | |
| 26-Jan-21 5:05 PM View: | Thompson Peter A Director 10% Owner | Prevail Therapeutics Inc. (PRVL) | 22-Jan-21 | Disposition (change in control) | 13,822,500 | -- | -- | (100%) 13.82M to 0 | |
| 26-Jan-21 5:12 PM View: | Nader Francois Director | Prevail Therapeutics Inc. (PRVL) | 22-Jan-21 | Disposition (change in control) | 23,747 | -- | -- | (100%) 23.75K to 0 | |
| 26-Jan-21 5:20 PM View: | Orbimed Advisors LLC Director 10% Owner | Prevail Therapeutics Inc. (PRVL) | 22-Jan-21 | Disposition (change in control) Duplicate | 13,822,500 | -- | -- | (100%) 13.82M to 0 | |
| 26-Jan-21 5:06 PM View: | Gordon Carl L Director 10% Owner | Prevail Therapeutics Inc. (PRVL) | 22-Jan-21 | Disposition (change in control) Duplicate | 13,822,500 | -- | -- | (100%) 13.82M to 0 | |
| 26-Jan-21 5:13 PM View: | Minkow Emily Chief Business Officer | Prevail Therapeutics Inc. (PRVL) | 22-Jan-21 | Disposition (change in control) | 13,000 | -- | -- | (100%) 13.0K to 0 | |
| 31-Dec-20 4:54 PM View: | Abeliovich Asa President & CEO Director | Prevail Therapeutics Inc. (PRVL) | 30-Dec-20 | Payment of Exercise | 89,037 | $23.02 | $2,049,630.00 | (4%) 2.47M to 2.39M | 0% |
| 31-Dec-20 4:54 PM View: | Abeliovich Asa President & CEO Director | Prevail Therapeutics Inc. (PRVL) | 30-Dec-20 | Option Exercise | 125,793 | $9.84 | $1,237,660.00 | 5% 2.35M to 2.47M | |
| 11-Mar-20 4:47 PM View: | Minkow Emily Chief Business Officer | Prevail Therapeutics Inc. (PRVL) | 24-Dec-19 | Option Exercise | 13,000 | $0.18 | $2,340.00 | 100% 0 to 13.0K | |
| 26-Jun-19 4:54 PM View: | Orbimed Advisors LLC Director 10% Owner | Prevail Therapeutics Inc. (PRVL) | 24-Jun-19 | Conversion | 10,510,100 | -- | -- | 433% 2.43M to 12.94M | |
| 26-Jun-19 4:54 PM View: | Orbimed Advisors LLC Director 10% Owner | Prevail Therapeutics Inc. (PRVL) | 24-Jun-19 | Purchase | 882,352 | $17.00 | $15,000,000.00 | 7% 12.94M to 13.82M | |
| 26-Jun-19 4:55 PM View: | Gordon Carl L Director 10% Owner | Prevail Therapeutics Inc. (PRVL) | 24-Jun-19 | Conversion Duplicate | 10,510,100 | -- | -- | 433% 2.43M to 12.94M | |
| 26-Jun-19 4:55 PM View: | Gordon Carl L Director 10% Owner | Prevail Therapeutics Inc. (PRVL) | 24-Jun-19 | Purchase Duplicate | 882,352 | $17.00 | $15,000,000.00 | 7% 12.94M to 13.82M | |
| 25-Jun-19 6:51 PM View: | Nader Francois Director | Prevail Therapeutics Inc. (PRVL) | 24-Jun-19 | Conversion | 23,747 | -- | -- | 100% 0 to 23.75K | |
| 26-Jun-19 4:56 PM View: | Thompson Peter A Director 10% Owner | Prevail Therapeutics Inc. (PRVL) | 24-Jun-19 | Conversion Duplicate | 10,510,100 | -- | -- | 433% 2.43M to 12.94M | |
| 26-Jun-19 4:56 PM View: | Thompson Peter A Director 10% Owner | Prevail Therapeutics Inc. (PRVL) | 24-Jun-19 | Purchase Duplicate | 882,352 | $17.00 | $15,000,000.00 | 7% 12.94M to 13.82M |
